Boston Scientific Corporation (BSX) was Reiterated by The Benchmark Company to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 22 from a previous price target of $20 . The Benchmark Company advised their investors in a research report released on Apr 27, 2016.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 12, 2016 to “Outperform”, Firm has raised the Price Target to $ 22 from a previous price target of $20 .Boston Scientific Corporation was Initiated by Nomura to “Buy” on Mar 17, 2016. Sun Trust Rbsn Humphrey Initiated Boston Scientific Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $21.
On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.
Boston Scientific Corporation opened for trading at $19.65 and hit $19.84 on the upside on Friday, eventually ending the session at $19.76, with a gain of 0.87% or 0.17 points. The heightened volatility saw the trading volume jump to 81,33,955 shares. Company has a market cap of $26,643 M.
In a different news, on Apr 5, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,000 shares at $18.73 per share price. According to the SEC, on Apr 5, 2016, Jeffrey B. Mirviss (SVP&Pres, Periph Intervent) sold 18,422 shares at $19.00 per share price. On Apr 5, 2016, Michael F Mahoney (President & CEO) sold 100,000 shares at $18.90 per share price, according to the Form-4 filing with the securities and exchange commission.
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.